Online citations, reference lists, and bibliographies.
← Back to Search

Surgical Options In Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy Or Pleurectomy/decortication.

R. Flores
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Two operations have evolved for the surgical treatment of malignant pleural mesothelioma (MPM): extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). The goal of surgery in the multimodality treatment approach is to achieve a macroscopic complete resection, with adjuvant therapies directed at residual microscopic disease. Overall survival reported in a recent multicenter analysis of these two operations supports the use of P/D for early stage MPM provided that a complete resection is feasible; otherwise EPP will confer a survival advantage. For stage II disease, however, EPP demonstrates a possible advantage. The focus in stage III disease should remain on the ability to achieve macroscopic complete resection, rather than N2 disease. Patients with stage IV cancers have better survival if the lung is left in place.
This paper references
10.1016/S1556-0864(15)31536-7
Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.
D. Sugarbaker (2006)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
K. Allen (1994)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1016/J.EJCTS.2007.01.064
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
10.1016/0360-3016(84)90050-6
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.ATHORACSUR.2004.01.034
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1200/JCO.2005.00.802
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
C. Lu (2005)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1016/S0022-5223(19)38932-9
Surgical treatment of pleural mesothelioma.
P. McCormack (1982)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1007/978-0-387-88443-1
AJCC cancer staging handbook
F. L. Greene (2002)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)



This paper is referenced by
10.1016/j.canrad.2017.05.007
High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
E. Parisi (2017)
10.4172/2155-9619.S2-011
Malignant Pleural Mesothelioma: Management and Role of Radiation Therapy
Donato (2013)
10.4414/smw.2012.13686
Long term survival after trimodal therapy in malignant pleural mesothelioma.
R. Fahrner (2012)
10.1586/ers.10.35
Surgery for malignant pleural mesothelioma
D. Sugarbaker (2010)
10.21037/JTD.2019.02.61
Extra-pleural pneumonectomy.
Leonardo Duranti (2019)
10.1007/s12253-013-9677-2
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
10.3978/j.issn.2225-319X.2012.11.12
Multimodality therapy for malignant pleural mesothelioma.
W. Weder (2012)
10.1586/ers.11.1
Photodynamic therapy for malignant pleural mesothelioma: the future of treatment?
J. Friedberg (2011)
10.1378/chest.13-3062
Spinal cord ischemia resulting in paraplegia following extrapleural pneumonectomy.
Kelly G Ural (2014)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.3978/j.issn.2072-1439.2014.05.03
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
10.3892/ol.2019.9979
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.
Yuichiro Kai (2019)
10.21037/tlcr.2018.07.07
Extrapleural pneumonectomy: still indicated?
A. Domen (2018)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
R. Martins (2012)
10.1016/j.ejcts.2010.12.024
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
10.1016/j.athoracsur.2017.09.036
National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
Sahar A Saddoughi (2018)
10.1007/s00104-012-2433-4
Intraoperative Chemotherapie nach radikaler Pleurektomie oder extrapleuraler Pneumonektomie
M. Ried (2012)
10.2217/LMT.15.26
Surgery for malignant pleural mesothelioma
Michael A. Archer (2015)
10.1080/17476348.2020.1688147
Extrapleural pneumonectomies for pleural mesothelioma
Eleonora Faccioli (2019)
10.1007/s00595-018-1624-0
Non-incisional pleurectomy–decortication for malignant pleural mesothelioma
F. Tanaka (2018)
10.1016/j.jtho.2018.08.001
Surgery in Malignant Pleural Mesothelioma
R. Bueno (2018)
10.3978/j.issn.2305-5839.2015.07.03
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Weiquan Zhang (2015)
10.1007/s11748-014-0389-7
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma
S. Hasegawa (2014)
10.1080/10937404.2016.1195321
Investigating palygorskite’s role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity
D. Larson (2016)
Investigating the role of
C. Stevenson (2011)
10.1007/s00104-013-2518-8
Regionale Versorgung des malignen Pleuramesothelioms
M. Ried (2013)
10.1002/jso.22100
Multidisciplinary management of malignant pleural effusion
J. Kaifi (2012)
10.1016/J.RMCLC.2015.04.020
ASPECTOS DIAGNÓSTICOS Y TERAPÉUTICOS EN EL MESOTELIOMA PLEURAL MALIGNO
P. F. Rodriguez (2015)
10.1093/ejcts/ezs418
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
M. Ried (2013)
10.1055/A-0573-2419
Anwendung der hyperthermen intrathorakalen Chemotherapie (HITHOC) in Deutschland
Michael Ried (2018)
10.1007/978-3-319-96244-3_8
Care of the Mesothelioma Patient Undergoing Extended Pleurectomy and Decortication
M. Culligan (2019)
Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?
P. Hountis (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar